AstraZeneca has announced a jump in sales in recent months after a surge in demand for cancer drugs, as the pharmaceutical ...

Cambridge headquartered AstraZeneca saw its UK share price rocket 328p to 11,118 and its market cap soar to £173.49 billion after a stunning set of results for the first half and second quarter of ...

Barclays today said half-year pre-tax profits rose 23% to £5.2 billion, boosted by a 28% improvement in the second quarter of ...

This landmark investment reflects not only America's importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca's ambition to deliver $80 billion ...

Wall Street stocks had a mixed session overnight, with the Dow Jones dipping 0.1%, the S&P 500 just one point above flat and ...

The AstraZeneca share price has been treading water for the past few years, but first-half results add strength to rising ...

AstraZeneca stock climbed nearly 3% in Tuesday’s early premarket session after the Cambridge, U.K.-based biopharma giant reported a beat for the second quarter of the fiscal year 2025 and reiterated ...

Games Workshop led the FTSE 100, rising 3.3% after reporting a record year. Revenue rose 17% to £617.5 million and pretax profit surged 29% to £262.8 million. ConvaTec added 0.8% as it raised its ...

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

Pharmaceutical giant AstraZeneca has reported increased revenue across all its major geographic regions and increased interim profits as the listed business maintained its growth ...

The Anglo-Swedish pharmaceutical giant said Tuesday that for the second quarter, core earnings per share rose to $2.17 from $1.98 in the same period a year prior. Revenue increased to $14.46 billion ...

(Alliance News) - AstraZeneca PLC on Tuesday reported better-than-expected second quarter revenue, and raised its dividend, boosted by strong sales from its cancer portfolio.